M
Ming-Li Sun
Researcher at Shanghai Jiao Tong University
Publications - 8
Citations - 137
Ming-Li Sun is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Medicine & Pharmacokinetics. The author has an hindex of 4, co-authored 4 publications receiving 106 citations.
Papers
More filters
Journal ArticleDOI
Bullatine A stimulates spinal microglial dynorphin A expression to produce anti-hypersensitivity in a variety of rat pain models
TL;DR: It is demonstrated for the first time that bullatine A specifically attenuates pain hypersensitivity, regardless of the pain models employed, and suggested that stimulation of spinal microglial dynorphin A expression mediates bull atine A anti-nociception in pain hypers sensitivity conditions.
Journal ArticleDOI
Cynandione A attenuates neuropathic pain through p38β MAPK-mediated spinal microglial expression of β-endorphin.
TL;DR: It is suggested that cynandione A attenuates neuropathic pain through upregulation of spinal microglial expression β-endorphin via p38β MAPK activation.
Journal ArticleDOI
Lappaconitine, a C18-diterpenoid alkaloid, exhibits antihypersensitivity in chronic pain through stimulation of spinal dynorphin A expression.
TL;DR: It is suggested that lappaconitine exhibits antinociception through directly stimulating spinal microglial dynorphin A expression in neuropathic rats, and in primary cultures of microglia but not neurons or astrocytes.
Journal ArticleDOI
Concurrent bullatine A enhances morphine antinociception and inhibits morphine antinociceptive tolerance by indirect activation of spinal κ-opioid receptors.
TL;DR: It is suggested that bullatine A produces antinociception without induction of tolerance and inhibits morphine ant inociceptive tolerance, and provide pharmacological basis for concurrent bull atine A and morphine treatment for chronic pain and morphine analgesic tolerance.
Journal ArticleDOI
Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial
Ming-Li Sun,Chen Liu,Haihong Bai,Yanru Wei,Wei Zhang,Huijuan Liu,Yinjuan Li,Long Liu,Yu Wang,Yuan-Xv Tong,Qian Gao,Qianqian Liu,Xinghe Wang +12 more
TL;DR: Generic MH-SR and Glucophage®-XR tablets were found to be bioequivalent and safe under fasting conditions in healthy Chinese participants, and the market demand forMH-SR tablets (500 mg/tablet) can be met using the generic alternative.